These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 23565115)

  • 1. Variation between Populations in the Innate Immune Response to Vaccine Adjuvants.
    Kollmann TR
    Front Immunol; 2013; 4():81. PubMed ID: 23565115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances of vaccine adjuvants for infectious diseases.
    Lee S; Nguyen MT
    Immune Netw; 2015 Apr; 15(2):51-7. PubMed ID: 25922593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BCG vaccines for the prevention of tuberculosis in the world].
    Hashimoto T
    Kekkaku; 1997 Nov; 72(11):629-37. PubMed ID: 9423301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine adjuvants: putting innate immunity to work.
    Coffman RL; Sher A; Seder RA
    Immunity; 2010 Oct; 33(4):492-503. PubMed ID: 21029960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants.
    Sepulveda-Crespo D; Resino S; Martinez I
    Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32560440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination strategies in developing countries.
    Poore P
    Vaccine; 1988 Oct; 6(5):393-8. PubMed ID: 3057759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine adjuvant properties of probiotic bacteria.
    Licciardi PV; Tang ML
    Discov Med; 2011 Dec; 12(67):525-33. PubMed ID: 22204769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of hepatitis B immunization in the Expanded Program on Immunization of the Child Survival Project.
    Mansour E; Abdul-Rahim S; Batouty G; Zaghloul I; Abdel-Hadi S
    J Egypt Public Health Assoc; 1993; 68(5-6):487-94. PubMed ID: 7775876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to vaccine adjuvants during the first year of life.
    Levy O; Goriely S; Kollmann TR
    Vaccine; 2013 May; 31(21):2500-5. PubMed ID: 23085363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
    Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
    Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of pneumococcal disease through vaccination.
    Gentile A; Bazán V
    Vaccine; 2011 Sep; 29 Suppl 3():C15-25. PubMed ID: 21896348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in vaccine adjuvants.
    Schijns VE; Lavelle EC
    Expert Rev Vaccines; 2011 Apr; 10(4):539-50. PubMed ID: 21506650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National programme for the control of poliomyelitis.
    Sokhey J
    Indian J Public Health; 1985; 29(3):168-74. PubMed ID: 3835134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular signatures of vaccine adjuvants.
    Olafsdottir T; Lindqvist M; Harandi AM
    Vaccine; 2015 Sep; 33(40):5302-7. PubMed ID: 25989447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Needle size for vaccination procedures in children and adolescents.
    Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010720. PubMed ID: 26086647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising Adjuvants and Platforms for Influenza Vaccine Development.
    Zhu W; Dong C; Wei L; Wang BZ
    Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33430259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasible improvements in vaccines in the Expanded Programme on Immunization.
    McIntosh K
    Rev Infect Dis; 1989; 11 Suppl 3():S530-7. PubMed ID: 2669097
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.